Old drug, new hope? ivermectin shows promise for PKDL in small trial
NCT ID NCT06251739
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This early study tested whether a common anti-parasite drug, ivermectin, could safely treat PKDL, a skin condition that can develop after kala-azar. Thirty adults in Bangladesh received either ivermectin or the standard treatment miltefosine. The goal was to see if ivermectin could clear the parasite and reduce skin lesions with fewer side effects. Results suggest ivermectin is safe and may offer a shorter, simpler treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-KALA-AZAR DERMAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
International Centre for Diarrhoeal Disease Research, Bangladesh
Dhaka, Dhaka Division, 1212, Bangladesh
Conditions
Explore the condition pages connected to this study.